StemGenex® Announces Patient Satisfaction Ratings for Stem Cell Centers

New patient reviews allows public insight into stem cell therapy through StemGenex

Dec 17, 2013, 08:45 ET from StemGenex

LA JOLLA, Calif., Dec. 17, 2013 /PRNewswire/ -- StemGenex®, the leading resource for adult adipose stem cell therapy in the US aimed at improving the lives of patients dealing with degenerative diseases today announced the public release of their satisfaction ratings for patients who have received stem cell therapy through StemGenex. 

Patients have trusted StemGenex for years to provide them with access to cutting edge stem cell therapies at the absolute highest levels of care.  StemGenex believes this is something that has been lacking in the industry for some time now.  These ratings now allow the public transparency into patient satisfaction in multiple categories which are now posted and updated monthly on the StemGenex website

StemGenex works tirelessly to provide the absolute highest level of care for patients and is very proud of the overwhelmingly positive results from these surveys.  This is just one of the many ways that StemGenex continues to innovate and position itself as the premiere resource for adipose stem cell therapy in the US. 

Stem cell treatment studies are currently being offered by StemGenex to patients diagnosed with Multiple Sclerosis and other degenerative neurological diseases.  StemGenex takes a unique approach of compassion and empowerment while providing access to the latest stem cell therapies for degenerative neurological diseases including Parkinson's and Alzheimer's disease, stroke recovery and others.  Rita Alexander, founder of StemGenex and the company's first stem cell patient, insists that all patients be treated like they are one of our loved ones.  "Hope, compassion, and the relentless pursuit for an end to these diseases are our primary focus."

To find out more about stem cell therapy, contact StemGenex either by phone at (800) 609-7795 or email

Image with caption: "Stem Cells at Work". Image available at:      

SOURCE StemGenex